MedisourceRx, Los Alamitos, CA
Is MedisourceRx an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names MedisourceRx in Los Alamitos, CA, first registered Feb 14, 2017 and most recently registered Jan 2, 2026. FDA lists its last inspection as Jun 10, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Warning Letter Closeout Issued 7/27/2026 Warning Letter Issued 12/12/2025”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Los Alamitos, CA
- Initial registration
- Feb 14, 2017
- Most recent registration
- Jan 2, 2026
- Last inspection
- Jun 10, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Warning Letter Closeout Issued 7/27/2026 Warning Letter Issued 12/12/2025
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as MedisourceRx, Los Alamitos, CA, a 503B facility, with 5 listed actions, including 2 Form 483s and 1 warning letter (2020 to 2025).
| Document | |||
|---|---|---|---|
| Dec 12, 2025 | Warning letter | Warning Letter (12/12/2025) | fda.gov |
| Jun 10, 2025 | Form 483 | 483 Issued 06/10/2025 | fda.gov |
| Apr 14, 2023 | FMD-145 letter | FMD-145 Letter Issued 04/14/2023 | Not linked by FDA |
| Jun 28, 2021 | FMD-145 letter | FMD-145 Letter Issued 06/28/2021 | Not linked by FDA |
| Oct 22, 2020 | Form 483 | 483 Issued 10/22/2020 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists MedisourceRx, Los Alamitos, CA (FEI number 3013316698), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Jun 10, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3013316698 | 1272492 |
| Nov 4, 2022 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3013316698 | 1191700 |
| Oct 22, 2020 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3013316698 | 1131719 |
Form 483s FDA has published for this site
- Jun 10, 2025: Form 483 to MedisourceRx, published Aug 7, 2025. fda.gov
- Oct 22, 2020: Form 483 to MedisourceRx, published Mar 11, 2025. fda.gov
- Sep 27, 2018: Form 483 to MedisourceRx, published Apr 30, 2019. fda.gov
- Sep 27, 2018: Form 483 to MedisourceRx, published Apr 30, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 23 numbered observations in all, across 4 inspections ending Sep 27, 2018 to Jun 10, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 27, 2025 to Jun 10, 2025: 2 observations
- Firm on the cover
- MedisourceRx, 10525 Humbolt St, Los Alamitos, CA 90720-5401
- FEI number
- 3013316698
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-244 5
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Adverse drug experience information has not been reported to FDA.
Specifically,
Your outsourcing facility has not submitted an adverse event report to FDA in accordance with the content and format requirements established through guidance or regulation under 21 CFR 310.305 as required by section 503B(b)(5).
For example, Complaint# C25004, was received on January 14, 2025, where a patient reported severe GI issues and three units of hospital stay after taking an injection of Semaglutide (2.5 mg/ml) Lot Number: <Redacted B4>, BUD: 6/10/2025.
This serious and unexpected adverse event was not reported to FDA within 15 calendar days after first receiving the information regarding this event.
Observation 2
Buildings used in the manufacture, processing, packing or holding of drug products are not free of infestation by rodents, birds insects, and other vermin.
Specifically,
Additionally, a dead cricket was observed in the middle of the incubator room. These incubators are used for the incubation of media fill vials, environmental and personnel monitoring samples collected during the production of compounded human drugs.
Inspection Oct 5, 2020 to Oct 22, 2020: 7 observations
- Firm on the cover
- MedisourceRx, 10525 Humbolt St, Los Alamitos, CA 90720-5401
- FEI number
- 3013316698
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Specifically, major defects found in 100% visual inspection process from the drug products were not fully investigated. This is a repeat observation.
A. No identification was performed on observed particles from multiple drug product batches. For example,
- Glutathione lot <Redacted B4> had 1 vial containing unknown particles.
- Glutathione lot <Redacted B4> had 3 vials containing unknown particles.
- Glutathione lot <Redacted B4>had 2 vials containing unknown particles
- Glutathione lot <Redacted B4> had 2 vials containing unknown particles.
-l<Redacted B4> lot <Redacted B4> had 2 syringes containing unknown particles.
14 B. The investigation for media fill lots with particulate counts that exceeded the action limit of <Redacted B4> is not adequate. Deviation-20-002 attributed the observed unknown particles to possible aggregate from <Redacted B4> media. However, such conclusion was not confirmed through additional test or examination. For example, ...
Observation 2
Procedures designed to prevent microbiological contarnination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Specifically,
A. Not all media fill units from aseptic process simulations carried out in Nov 2019 for syringes and Feb 2020 for vials were incubated and examined for turbidity. For example,
- Lot <Redacted B4> syringes were generated, only <Redacted B4> syringes were incubated.
- Lot <Redacted B4> syringes were generated, only <Redacted B4> syringes were incubated.
- Lot <Redacted B4> syringes were generated, only <Redacted B4> syringes were incubated.
- Lot <Redacted B4> vials were generated only <Redacted B4> vials were incubated.
1 - Lot <Redacted B4> vials were generated, only <Redacted B4> vials were incubated.
- Lot <Redacted B4> vials were generated, only <Redacted B4> vials were incubated.
:Ei
B. Not all media fill units were incubated <Redacted B4> for turbidity evaluation. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not written and followed.
Specifically,
A.
During <Redacted B4> and filling process of Glutathione drug product batch <Redacted B4> on 10/6/2020, the primary operator's arms were observed resting on the ISO 5 LAF hood bench. The same operator opened packages of sterile vials and stoppers using a scissor that was placed on the IS05 LAF bench without wiping it first using sterile <Redacted B4>.
B. The surface microbial sampling procedure, SOP-LAB-006, does not provide instruction on the specific sampling locations for personnel monitoring. For example, the in-use EM monitoring form, PPC-FRM-002.14, requires primary operator's <Redacted B4> be sampled, it is not clear which areas of <Redacted B4> samples shall be taken. On 10/6/2020 after the completion of Glutathione batch <Redacted B4> filling, it was observed that the <Redacted B4> of the primary operator's <Redacted B4> was sampled. There is no justification why the back of the <Redacted B4> is considered more relevant than the front of the <Redacted B4> which directly faces the sterile filling operation.
Observation 4
Written production and process control procedures are not documented at the time of performance.
Specifically,
A. <Redacted B4> of your firm's drug product requires <Redacted B4> pump to be set to <Redacted B4> 1pm, the actual speed used during products <Redacted B4> was not documented in batch production record.
B. Glutathione injection drug product fill volume test results were not documented in the batch production records.
Observation 5
The master production and control records are deficient in that they do not include complete manufacturing, control, instructions, testing and specifications.
Specifically,
A. There is no requirement for benzyl alcohol content test as part of Glutathione MDV drug product release specification.
B. There is no instruction in master batch records for both vial product <Redacted B4> and syringe product <Redacted B4> on how the compounded drug products shall be protected before transferring into ISO 7 clean room for <Redacted B4> and filling operation.
C. The batch production record review checklist does not include QA evaluation ofenvironmental monitoring test results
(i.e. viable and non-viable test).
Observation 6
Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.
Specifically, the cleaning procedure for mixing stainer that is used to compound multiple drug products has not been evaluated to ensure there is no cany over from one API to the other in the mixing process.
Material System
Observation 7
Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.
Specifically, active drug substance supplier qualification does not include verification of all relevant test results against the manufacturer's specifications. For example, the firm only tested assay, microbial counts, and endotoxin level for Glutathione APL No other test results on manufacturer's COA, such as specific optical rotation, related substances, chlorides, sulfates, ammonium, iron, heavy metals, loss on drying, etc., were verified.
Inspection Sep 12, 2018 to Sep 27, 2018: 7 observations
- Firm on the cover
- MedisourceRx, 10525 Humbol t St
- FEI number
- 3013316698
- Establishment type on the cover
- Outsourcing, Facility Los Alamitos, CA 90720- 5401
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612- 2445
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, there was a failure by your quality control unit to investigate fiber particulates that were found during commercial production of Glutathione 200mg/mL in 30mL MDV and during media fill qualifications. Examples include, but are not limited to, the items listed below.
A.) Glutathione 200mg/mL in 30mL MDV
Lot MSRX1207; 13 vials with white fiber particulates found. Lot MSR.Xl 189; three (3) vials with white fiber particulates found. Lot MSR.Xl 181; seven (7) vials with fiber particulates found.
B.) Media Fills in Febrnary 2018
Fiber particulates found in a total of three (3) vials for media fills performed by Technician < Redacted B4> Fiber particulates found in a total of six (6) vials for media fills performed by Technician <Redacted B4> ), Fiber particulates found in a total of 37 vials for media fills performed by Technician <Redacted B4>
These media fill qualifications for all three (3) Technicians were documented by your firm to have passing results. ...
Observation 2
Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products is not appropriate for the duties they perform.
Specifically, we observed a cleaning employee touch their garments on the floor while she was donning steiile gowning. An example includes, but is not limited to, the event listed below.
• On 09/18/2018, we observed (contract) cleaning employee < Redacted B4> brush the sleeves of her sterile govvn (edges of the sleeves on the jumpsuit) on the floor during the gowning procedure in the ISO 8 Gown Room prior to aseptic facility cleaning procedures.
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically, we found deficiencies in facility cleaning procedures and records; including, but not limited to, the examples listed below.
A.) On 09/18/2018, we observed cleaning in the ISO 8 classified Hallway and ISO 7 classified Fill Roorrtjand Fill Room <Redacted B4> We observed that the cleaning employees <Redacted B4> and <Redacted B4> failed to disinfect cleaning materials/items before the items were transferred from the ISO 8 Hallway into ISO 7 Fill Rooms. Additionally, your SOP titled, "PRS-004, Working in ISO Cleanroom Environments, Revision 02 Effective 04/04/1 8" does not instruct employees to disinfect items before transfeITing them from ISO 8 classified areas into ISO 7 classified Fill Rooms.
B.) Written procedures and records pertaining to aseptic facility cleaning appear deficient. Examples include, but are not limited to, the items listed below.
SOP titled, "FAC-006, Cleaning of the Cleanroom Revision 03 Effective 05/04/18" does not specify maximum area of mop strokes before employees need to re-saturate mop heads. ...
Observation 4
Specifically, we observed that employee training records appear deficient in that they lack full details of training content. Examples include, but are not limited to, the items listed below.
A.) Your firm documents that employees are trained on SOP "PRS-002 Gowning Procedure Prior to Cleanroom Access" and SOP "PRS-003 Hand Washing Procedure" with names and dates in your "Competency Audit: Gowning and Handwashing" f01m . However, the record does not state the
specification needed to pass and the actual result obtained by the employee.
Additionally, there were at least two (2) documented examples of CAPA (Conective and Preventive Action) Reports where personnel monitoring of gowning during aseptic fill failed specifications.
CAPA 18-004: 2 samples exceeded action limit of <Redacted B4> CFU.
o Primary Technician Gown Hood on 03/19/2018; result 10 CFU; identified as Rothia dentocariosa. o Primary Technician Gown on 05/04/2018; result 4 CFU; identified as Rothia mucilaginosa. CAPA 18-005: I sample exceeded action limit o0 FU. o Primary Technician Gown on 08/02/2018; result 5 CFU; identified as Streptococcus
australis. ...
Observation 5
Specifically, on 09/1712018, we observed within the ISO classified areas, that more than one door can remain open at the same time. Your written procedures, including, but not limited to, the SOPs listed
below, do not include instructions to employees to exercise controls to open one door at a time within the ISO classified areas.
SOP titled, "FAC-001, Facility Design and Process Flow Revision 01 Effective 01115/18" SOP titled, "PRS-004, Working in ISO Cleanroom Environments Revision 02 Effective 04/04/18"
Observation 6
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process.
Specifically, we observed that your firm's media fill qualification procedures failed to demonstrate worst-case conditions. The media fill qualification documents (protocol attaclunents and/or formulation worksheets) from January, February, August, and September 2018 failed to document the items including, but not limited to, the paran1eters listed below.
The number of people present in the ISO 7 classified Fill Room at the time of the media fill(s) was not documented to show a worst-case condition ofmaximum occupants in the room. The media fill procedure does not clearly state how the media fill unit incubation results should
be documented. For example, [(o) (4~readings for all '(llm>days of media vial incubations to be documented vs. just the final outcome. Visual inspection acceptance criteria are not clearly specified in the media fill procedures; for example, the number of vials with fibers or other particulates that would pass or fail a media fill lot.
lot. ...
Observation 7
The batch production and control records are deficient in that they do not include documentation of the accomplishment ofeach significant step in manufacturing, processing, packing and holding.
Specifically, documentation examples include, but are not limited to, the items listed below.
A.) Glutathione 200mg/mL in 30mL MDV Drug Product
1.) On 09117/2018, we observed technicians documenting batch production records for Glutathione 200mg/mL in 30mL MDV lot MSRX1209. We noted that the technicians do not contemporaneously document full details of the compounding and filling process for this product. Examples include, but are not limited to, the items listed below.
The execution of each step and verification that the step was completed, such as initials of the Technician and second person after every step. <Redacted B4> not documented . <Redacted B4> times (start and finish) are not documented .
Values, such as grams ofweighed raw materials, are not contemporaneously documented .
<Red a
cted B4> values are written on separate paper and transcribed to batch record . ...
Inspection Sep 12, 2018 to Sep 27, 2018: 7 observations
- Firm on the cover
- MedisourceRx, 10525 Humbolt St, Los Alamitos, CA 90720-5401
- Establishment type on the cover
- Outsourcing Facility - -
- FDA district office on the cover
- 19701 Fairchild Irvine, CA 92612-2445
- Matched to this page by
- firm name, city and state on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any '1f its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically, there was a failure by your quality control unit to investigate fiber particulates that there found during commercial production of Glutathione 200mg/mL in 30mL MDV and during media fill qualifications. Examples include, but are not limited to, the items listed below.
A.) Glutathione 200mg/mL in 30mL MDV
Lot MSR.Xl207; 13 vials with white fiber particulates found . Lot MSRX 1189; three (3) vials with white fiber particulates found . Lot MSRX 1181; seven (7) vials with fiber particulates found . -
B.) Media Fills in February 2018
Fiber particulates found in a total of three (3) vials for media fills perfonned by Technician <Redacted B4> Fiber particulates found in a total of six (6) vials for media fills performed by Technician <Redacted B4> Fiber particulates found in a total of 37 vials for media fills performed by Technician <Redacted B4> 5»_
These media fill qualifications for all three (3) Technicians were documented by your firm to have
passing results. ...
Observation 2
Clothing of personnel engaged in the manufacturing, processing, packing and holding of drug products is not appropriate for the duties they perform. I I Specifically, we observed a cleaning employee touch their garments on the floor while she was donning sterile gowning. An example includes, but is not limited to, the event listed below.
• On 09/18/2018, we observed (contract) cleaning employee < Red acted B4> brush the sleeves of her sterile gown (edges of the sleeves on the jumpsuit) on the floor during the gowning procedure in the ISO 8 Gown Room prior to aseptic facility cleaning procedures.
Observation 3
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room to produce aseptic conditions.
Specifically, we found deficiencies in facility cleaning procedures and records; including, but not limited to, the examples listed below. I
A.) On 09/1812018, we observed cleaning in the ISO 8 classified H allway and ISO 7 classified Fill Room <Redacted B4> and Fill Room <Redacted B4> We observed that the cleaning employees <Redacted B4> and <Redacted B4> failed to disinfect cleaning materials/items before the items were transferred from the ISO 8 Hallway into ISO 7 Fill Rooms. Additionally, your SOP titled, "PRS-004, Working in ISO Cleanroom Environments, Revision 02 Effective 04/04/18'' does not instruct employees to disinfect items before transferring them from l SO 8 classified areas into ISO 7 classified Fill Rooms. I
AMENDMENT 1
B.) Written procedures and records pertaining to aseptic facility cleaning appear deficient. Examining include, but are not limited to, the items listed below. ...
Observation 4
AMENDMENT 1
Specifically, we observed that employee training records appear deficient in that they lack full details of training content. Examples include, but are not limited to, the items listed below.
A.) Your firm documents that employees are trained on SOP "PRS-002 Gowning Procedure Prior to Cleanroom Access" and SOP "PRS-003 Hand Washing Procedure" with names and dates in your "Competency Audit: Gowning and Handwashing" form. However, the record does not stale the
specification needed to pass and the actual result obtained by the employee. Additionally, there were at least two (2) documented examples of CAPA (Corrective and Preventive Action) Reports where personnel monitoring of gowning during aseptic fill failed specifications.
Your firm documents that employees are trained on SOP "PRS-002 Gowning Procedure Prior to Cleanroom Access" and SOP "PRS-003 Hand Washing Procedure" with names and dates in your "Competency Audit: Gowning and Handwashing" form. However, the record does not stale the specification needed to pass and the actual result obtained by the employee. ...
Observation 5
The control systems necessary to prevent contamination or mix-ups are deficient.
Specifically, on 09/ 17/2018, we observed within the ISO classified areas, that more than one door can remain open at the same time. Your written procedures, including, but not limited to, the SOPs listed below, do not include instructions to employees to exercise controls to open one door at a time within the ISO classified areas.
SOP titled, "FAC-00 I, Facility Design and Process Flow Revision 0I Effective 0 I /I 5/18" SOP titled, "PRS-004, Working in ISO Cleanroom Environments Revision 02 Effective 04/04/l 8"
Observation 6
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation ofthe aseptic and sterilization process.
Specifically, we observed that your firm's media fill qualification procedures failed to demonstrate worst-case conditions. The media fill qualification documents (protocol attachments and/or formulation worksheets) from January, February, August, and September 2018 failed to document the items including, but not limited to, the parameters listed below.
The number of people present in the ISO 7 classified Fill Room at the time of the media fill(s) was not documented to show a worst-case condition of maximum occupants in the room. The media fill procedure does not clearly state how the media fill unit incubation results should
be documented. For example, <Redacted B4> readings for all <Redacted B4> days of media vial incubations to be documented vs. just the final outcome.
Visual inspection acceptance criteria are not clearly specified in the media fill procedures; for example, the number of vials with fibers or other particulates that would pass or fail a media fill lot.
AMENDMENTl
lot. ...
Observation 7
The batch production and control records are deficient in that they do not include documentation of the accomplishment ofeach significant step in manufacturing, processing, packing and holding.
Specifically, documentation examples include, but are not limited to, the items listed below.
A.) Glutathione 200mg/mL in 30mL MDV Drug Product
1.) On 09/17/2018, we observed technicians documenting batch production records for Glutathione 200mg/mL in 30mL MDV lot MSRX1 209. We noted that the technicians do not contemporaneously document full details ofthe compounding and filling process for this product. Examples include, but are not limited to, the items listed below.
The execution of each step and verification that the step was completed, such as initials of the Technician and second person after every step. <Redacted B4> of documented .
<Redacted B4> times (start and finish) are not documented .
Values , such as grams of weighed raw materials, are not contemporaneously documented.
< Redacted B4> values are written on separate paper and transcribed to batch record . ...
Linked 483s whose text is not shown
- Oct 22, 2020: FDA document 154824: the PDF could not be downloaded.
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (MedisourceRx). That is not a finding beyond this index’s search.
The MedisourceRx pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “MedisourceRx”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (1). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 70657-1027 | Semaglutide | Semaglutide | SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2, 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.